LATEST NEWS:
Helus Pharma's Statement on White House Executive Order Accelerating Medical Treatments for Serious Mental Illness.
Helping Minds Heal.
Pioneering a paradigm shift in mental health that empowers the healing process.
Updates:
Helus Pharma Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
Helus Pharma Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
Helus Pharma Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
Led By Science
Advancing Mental Health with Novel Serotonergic Agonists (NSAs1 )
HELUS Pharma’s mission is to provide treatments designed to foster durable improvements in mental health to help minds heal. We strategically innovate novel serotonergic agonists (NSA) through rigorous patient-centered research and clinical excellence.
1 Novel serotonergic agonist: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity.
NEXT GENERATION THERAPIES
We are pioneering the development of next-generation therapies by leveraging our proprietary drug development platform to create novel serotonergic agonists.
OUR TECHNOLOGY
We aim to create novel delivery formulations designed to support consistent administration, reduce variability of acute effects between individuals, and potentially reduce time in clinic.
Helus
by the
numbers:
2
Lead drug
programs.
350+
Patent
applications
pending.
100+
Granted
patents.
Led by Experts in
Mental Health Innovation
Our team brings deep pharmaceutical development and regulatory expertise to our mental health therapeutic programs. Our scientific leadership includes experience in neuropsychiatry, oversight of 60+ IND programs, and a strong track record of developing multiple commercially available pharmaceutical therapies including over 10 blockbuster drugs.
Michael Cola
Chief Executive Officer
Amir Inamdar MBBS, DNB (Psych), MFPM
Chief Medical Officer
Freda Lewis-Hall
Chair of the Scientific Advisory Committee
Alex Nivorozhkin Ph.D.
Chief Scientific Officer
Our ground breaking work
in the press.
Our work has garnered growing interest over time, with our novel products, process and treatments being recognized and reported on by many trusted publications and forums. Here are just a few — click on each to see what was written about us.
FiercePharma
Discover
FORBES
TIME
NASDAQ
Business Insider
International Business Times
Our ground breaking work
in the press.
Our work has garnered growing interest over time, with our novel products, process and treatments being recognized and reported on by many trusted publications and forums. Here are just a few — click on each to see what was written about us.
